Literature DB >> 28109554

Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008-2013.

Chien-Yuan Chen1, Feng-Ming Tien1, Wang-Huei Sheng2, Shang-Yi Huang1, Ming Yao1, Jih-Luh Tang3, Woei Tsay1, Hwei-Fang Tien1, Po-Ren Hsueh4.   

Abstract

This study aimed to investigate the epidemiology and microbiology of bloodstream infections (BSIs) in patients with haematological malignancies. Clinical characteristics and microbiology of 2083 patients with haematological malignancy who were treated for BSI from 2008 to 2013 at a medical centre in Taiwan were retrospectively reviewed. Lymphoma (38.1%) was the most common, followed by acute myeloid leukaemia (30.9%). Of the 2090 non-duplicate BSI isolates, 1310 (62.7%) were recovered from patients with neutropenia. Of the Gram-negatives (53.7%), Escherichia coli was predominant (13.8%), followed by Klebsiella pneumoniae (9.5%), Acinetobacter calcoaceticus-baumannii (ACB) complex (5.7%) and Pseudomonas aeruginosa (4.0%). Of the Gram-positives (40.2%), coagulase-negative staphylococci were the most common (20.5%), followed by Enterococcus faecium (5.6%). Candida tropicalis (2.0%) was the most commonly encountered yeast (5.0%). Multidrug resistance (MDR) was identified in 21.8% of ACB complex isolates. Among the 57 Staphylococcus aureus isolates, 24 (42.1%) were resistant to oxacillin (MRSA), and among the 118 E. faecium isolates, 55 (46.6%) were resistant to vancomycin (VRE). The overall 14-day mortality rate was 12.9% (n = 269). There was no significant difference in 14-day mortality among patients with (13.4%) and without (11.9%) neutropenia (P = 0.315). Multivariate analysis revealed that age ≥60 years, prior allogeneic transplantation, BSI due to VRE (E. faecium) and shock were independent predictors of 14-day mortality. Gram-negative organisms continued to be the most common cause of BSI in patients with haematological malignancies during the period 2008-2013. There was a significant increase in the prevalence of VRE (E. faecium) and MDR-ACB complex isolates.
Copyright © 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.

Entities:  

Keywords:  Aetiology; Antimicrobial resistance; Bloodstream infection; Haematological malignancy; Neutropenia; Outcomes and mortality

Mesh:

Year:  2017        PMID: 28109554     DOI: 10.1016/j.ijantimicag.2016.11.009

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  12 in total

Review 1.  Empirical antimicrobial treatment in haemato-/oncological patients with neutropenic sepsis.

Authors:  Matthias Gerhard Vossen; Christopher Milacek; Florian Thalhammer
Journal:  ESMO Open       Date:  2018-06-13

2.  Nosocomial Infections in Gastrointestinal Cancer Patients: Bacterial Profile, Antibiotic Resistance Pattern, and Prognostic Factors.

Authors:  Ai-Min Jiang; Na Liu; Rim Ali Said; Meng-Di Ren; Huan Gao; Xiao-Qiang Zheng; Xiao Fu; Xuan Liang; Zhi-Ping Ruan; Yu Yao; Tao Tian
Journal:  Cancer Manag Res       Date:  2020-06-25       Impact factor: 3.989

3.  In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).

Authors:  Shio-Shin Jean; Min-Chi Lu; Zhi-Yuan Shi; Shu-Hui Tseng; Ting-Shu Wu; Po-Liang Lu; Pei-Lan Shao; Wen-Chien Ko; Fu-Der Wang; Po-Ren Hsueh
Journal:  Infect Drug Resist       Date:  2018-10-26       Impact factor: 4.003

4.  Eremomycin pyrrolidide: a novel semisynthetic glycopeptide with improved chemotherapeutic properties.

Authors:  Evgenia N Olsufyeva; Andrey E Shchekotikhin; Elena N Bychkova; Eleonora R Pereverzeva; Ivan D Treshalin; Elena P Mirchink; Elena B Isakova; Mikhail G Chernobrovkin; Roman S Kozlov; Andrey V Dekhnich; Maria N Preobrazhenskaya
Journal:  Drug Des Devel Ther       Date:  2018-09-10       Impact factor: 4.162

5.  Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemotherapy.

Authors:  Olivier Ballo; Ikram Tarazzit; Jan Stratmann; Claudia Reinheimer; Michael Hogardt; Thomas A Wichelhaus; Volkhard Kempf; Hubert Serve; Fabian Finkelmeier; Christian Brandts
Journal:  PLoS One       Date:  2019-01-23       Impact factor: 3.240

6.  Nosocomial infections due to multidrug-resistant bacteria in cancer patients: a six-year retrospective study of an oncology Center in Western China.

Authors:  Ai-Min Jiang; Xin Shi; Na Liu; Huan Gao; Meng-Di Ren; Xiao-Qiang Zheng; Xiao Fu; Xuan Liang; Zhi-Ping Ruan; Yu Yao; Tao Tian
Journal:  BMC Infect Dis       Date:  2020-06-29       Impact factor: 3.090

7.  [Analysis of pathogens and clinical characteristics of bloodstream infection in neutropenic children with hematological malignancies from 2014 to 2018].

Authors:  G Q Zhu; C H Xu; Q S Lin; X X Wang; L L Wang; N N Zhao; S Z Feng; Y M Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-08-14

8.  Prevalence, predictors, and mortality of bloodstream infections due to methicillin-resistant Staphylococcus aureus in patients with malignancy: systemic review and meta-analysis.

Authors:  Zhouqi Li; Hemu Zhuang; Guannan Wang; Hui Wang; Ying Dong
Journal:  BMC Infect Dis       Date:  2021-01-14       Impact factor: 3.090

Review 9.  Epidemiology and Pathogenesis of Staphylococcus Bloodstream Infections in Humans: a Review.

Authors:  Klaudia Lisowska-Łysiak; Ryszard Lauterbach; Jacek Międzobrodzki; Maja Kosecka-Strojek
Journal:  Pol J Microbiol       Date:  2021-02-24

10.  Bloodstream infections in adult patients with malignancy, epidemiology, microbiology, and risk factors associated with mortality and multi-drug resistance.

Authors:  Samane Nematolahi; Zahra Shahhosein; Ali Amanati; Sarvin Sajedianfard; Somayeh Khajeh; Shabnam Ghasempour; Salma Mehrangiz
Journal:  BMC Infect Dis       Date:  2021-07-02       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.